The effect of antioxidant vitamins E and C on cognitive performance of the elderly with mild cognitive impairment in Isfahan, Iran: A double-blind, randomized, placebo-controlled trial

European Journal of Nutrition

Volumn 53, Issue 5, 2014, Pages 1255-1262

  Alavi Naeini, A M ^a   Elmadfa, I ^b,e   Djazayery, A ^a   Barekatain, M ^c   Aghaye Ghazvini, M R ^d   Djalali, M ^a   Feizi, A ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF VIENNA   (Austria)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e International Union of Nutritional Sciences (IUNS)   (Austria)

Author keywords

Mild cognitive impairment; Supplementation; The elderly; Vitamin C; Vitamin E

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CAROTENE; GLUTATHIONE; MALONALDEHYDE; PLACEBO; SELENIUM; ZINC; 8-OXO-7-HYDRODEOXYGUANOSINE; DEOXYGUANOSINE;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; BODY HEIGHT; BODY MASS; BODY WEIGHT; COGNITION; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; EDUCATIONAL STATUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; FOOD INTAKE; GERIATRIC CARE; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; OXIDATIVE STRESS; PENSIONER; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TREATMENT DURATION; VITAMIN SUPPLEMENTATION; ANALOGS AND DERIVATIVES; BLOOD; DIET SUPPLEMENTATION; DRUG EFFECTS; MIDDLE AGED;

AGED; ANTIOXIDANTS; ASCORBIC ACID; COGNITION; DEOXYGUANOSINE; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; GLUTATHIONE; HUMANS; IRAN; MALE; MALONDIALDEHYDE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; OXIDATIVE STRESS; VITAMIN E;

EID: 84905987482     PISSN: 14366207     EISSN: 14366215     Source Type: Journal    
DOI: 10.1007/s00394-013-0628-1     Document Type: Article

References (56)

1. WHO (2012) Dementia: A public health priority: http://whqlibdoc.who.int/ publications/2012/9789241564458-eng.pdf
2. Mecocci P, Polidorib MC (2012) Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease. Biochim Biophys Acta 5:631-638. doi:10.1016/j.bbadis.2011.10.006
3. Nelson AP, O'Connor MG (2008) Mild cognitive impairment: a neuropsychological perspective. CNS Spectr 13(1):56-64 (Pubitemid 351224283)
4. Padurariu M, Ciobica A, Hritcu L, Stoica B, Bild W, Stefanescu C (2010) Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett 18(469(1)):6-10
5. Smith GE, Petersen RC, Parisi JE, Ivnik RJ (1996) Definition, course, and outcome of mild cognitive impairment. Aging Neuropsychol Cogn 3(2):141-147. doi:10.1080/13825589608256619 (Pubitemid 26355260)
6. Baldeiras I, Santana I, Proença MT, Garrucho MH, Pascoal R, Rodrigues A, Duro D, Oliveira CR (2008) Peripheral oxidative damage in mild cognitive impairment and mild Alzheimer's disease. J Alzheimers Dis 15(1):117-128
7. Lovell MA, Markesbery WR (2008) Oxidatively modified RNA in mild cognitive impairment. Neurobiol Dis 29(2):169-175. doi:10.1016/j.nbd.2007.07.030
8. Torres LL, Quaglio NB, de Souza GT et al (2011) Oxidative stress biomarkers in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 26(1):59-68
9. Shao C, Xiong S, Li GM, Gu L, Mao G, Markesbery WR, Lovell MA (2008) Altered 8-oxoguanine glycosylase in mild cognitive impairment and late-stage Alzheimer's disease brain. Free Radic Biol Med 45(6):813-819. doi:10.1016/j.freeradbiomed.2008.06.003
10. Baldeiras I, Santana I, Proença MT, Garrucho MH, Pascoal R, Rodrigues A, Duro D, Oliveira CR (2010) Oxidative damage and progression to Alzheimer's disease in patients with mild cognitive impairment. J Alzheimers Dis 21(4):1165-1177
11. Guidi I, Galimberti D, Lonati S et al (2006) Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 27(2):262-269. doi:10.1016/j.neurobiolaging.2005.01.001 (Pubitemid 43038550)
12. López N, Tormo C, De Blas I, Llinares I, Alom J (2013) Oxidative stress in Alzheimer's disease and mild cognitive impairment with high sensitivity and specificity. J Alzheimers Dis 33(3):823-829. doi:10.3233/JAD-2012-121528
13. Cervellati C, Cremonini E, Bosi C, Magon S, Zurlo A, Bergamini CM, Zuliani G (2012) Systemic Oxidative Stress in Older Patients with Mild Cognitive Impairment or Late Onset Alzheimer's Disease. Curr Alzheimer Res
14. Stocker R (2007) Vitamin E. Novartis Found Symp 282:77-87. doi:10.1002/9780470319444.ch6
15. Masaki KH, Losonczy KG, Izrnirlian G (2000) Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neuroiem 54:1265-1272 (Pubitemid 30174045)
16. Morris MC, Evans DA, Bienias JL, Tangney CC, Wilson RS (2002) Vitamin E and cognitive decline in older persons. Arch Newrol 59(7):1125-1132. doi:10.1001/archneur.59.7.1125 (Pubitemid 34755825)
17. Engelhart MJ, Geerlings MI, Ruitenberg A (2002) Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 287(24):3223-3229. doi:10.1001/jama.287.24.3223 (Pubitemid 34686103)
18. Grodstein F, Chen J, Willett WC (2003) High-dose antioxidant supplements and cognitive function in community-dwelling elderly women. Am J Clin Nutr 77(4):975-984
19. Zandi PP, Anthony JC, Khachaturian AS et al (2004) Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the cache county study. Arch Neurol 61(1):82-88. doi:10.1001/archneur.61.1.82 (Pubitemid 38067418)
20. Isaac MG, Quinn R, Tabet N (2008) Vitamin E for Alzheimer's disease and mild cognitive impairment. Cochrane database Syst Rev 16 (3):CD002854. doi: 10.1002/14651858.CD002854.pub2
21. Sano M, Ernesto C, Thomas RG et al (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's disease cooperative study. N Engl J Med 336(17):1216-1222. doi:10.1056/NEJM199704243361704 (Pubitemid 27183651)
22. Petersen RC, Thomas RG, Grundman M et al (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352(23):2379-2388. doi:10.1056/NEJMoa050151 (Pubitemid 40958434)
23. Seyedian M, Falamh M, Nourouzian M, Nejat S, Delavar A, Ghasemzadeh HA (2008) Validity of the Farsi version of Mini-Mental State Examination. J Med Counc I.R.I. 25(4):408-414 (Abstract in English)
24. Yu LW, Latriano L, Duncan S, Hartwick RA, Witz G (1986) High-performance liquid chromatography analysis of the thiobarbituric acid adducts of malondialdehyde and trans, trans-muconaldehyde. Anal Biochem 156(2):326-333 (Pubitemid 16051768)
25. Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A (1993) A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci (lond) 84(4):407-412 (Pubitemid 23113948)
26. Beutler E, Duron O, Kelly BM (1963) Improved method for the determination of blood glutathione. J Lab Clin Med 61:882-888
27. Morris MC, Beckett LA, Scherr PA, Hebert LE, Bennett DA, Field TS, Evans DA (1998) Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Dis Assoc Disord 12(3):121-126. doi:10.1097/00002093- 199809000-00001 (Pubitemid 29154978)
28. Sattler C, Toro P, Schönknecht P, Schröder J (2012) Cognitive activity, education and socioeconomic status as preventive factors for mild cognitive impairment and Alzheimer's disease. Psychiatry Res 196(1):90-95. doi:10.1016/j.psychres.2011.11.012
29. Letenneur L, Gilleron V, Commenges D, Helmer C, Orgogozo J, Dartigues J (1999) Are sex and educational level independent predictors of dementia and Alzheimer's disease? Incidence data from the PAQUID project. J Neurol Neurosurg Psychiatry 66(2):177-183. doi:10.1136/jnnp.66.2.177 (Pubitemid 29103518)
30. Scarmeas N, Luchsinger JA, Schup FN, Brickman AM, Cosentino S, Tang MX, Stern Y (2009) Physical activity, diet, and risk of Alzheimer disease. JAMA 302(6):627-637. doi:10.1001/jama2009.1144
31. Buchman AS, Wilson RS, Bienias JL, Shah RC, Evans DA, Bennett DA (2005) Change in body mass index and risk of incident Alzheimer disease. Neurology 65(6):892-897. doi:10.1212/01.wnl.0000176061.33817.90 (Pubitemid 41362136)
32. Kukull WA, Higdon R, Bowen JD et al (2002) Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol 59(11):1737-1746. doi:10.1001/archneur.59.11.1737 (Pubitemid 35340484)
33. Kang JH, Cook N, Manson J, Buring JE, Grodstein F (2006) A randomized trial of vitamin E supplementation and cognitive function in women. Arch Intern Med 166(22):2462-2468. doi:10.1001/archinte.166.22.2462 (Pubitemid 44913230)
34. Luchsinger JA, Tang MX, Shea S, Mayeux R (2003) Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 60(2):203-208. doi:10.1001/archneur.60.2.203 (Pubitemid 36193963)
35. Maxwell CJ, Hicks MS, Hogan DB, Basran J (2005) Supplemental use of antioxidant vitamins and subsequent risk of cognitive decline and dementia. Dement Geriatr Cogn Disord 20(1):45-51. doi:10.1159/000085074 (Pubitemid 40981178)
36. Galasko DR, Peskind E, Clark CM et al (2012) Antioxidants for Alzheimer'disease randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol 69(7):836-841. doi:10.1001/archneurol.2012.85
37. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E (2005) Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142(1):37-46
38. Lock M, Loblaw A (2005) Vitamin E might increase risk of death. Can Fam Physician 51(6):829-831
39. Klein EA, Thompson IM, Tangen CM et al (2011) Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306(14):1549-1556. doi:10.1001/jama 2011.1437
40. Rautiainen S, Lindblad BE, Morgenstern R, Wolk A (2010) Vitamin C supplements and the risk of age-related cataract: a population-based prospective cohort study in women. Am J Clin Nutr 91(2):487-493. doi:10.3945/ajcn.2009. 28528
41. Rathi S, Kern W, Lau K (2007) Vitamin C-induced hyperoxaluria causing reversible tubulointerstitial nephritis and chronic renal failure: a case report. J Med Case Rep 1:155. doi:10.1186/1752-1947-1-155
42. Farina N, Isaac MG, Clark AR, Rusted J, Tabet N (2012) Vitamin E for Alzheimer's dementia and mild cognitive impairment. Cochrane Database of Systematic Reviews 11; CD002854. doi:10.1002/14651858.CD002854.pub3
43. Stuerenburg HJ, Ganzer S, Müller-Thomsen T (2005) Plasma beta carotene in Alzheimer's disease. Association with cerebrospinal fluid beta-amyloid 1-40, (Abeta40), beta-amyloid 1-42 (Abeta42) and total Tau. Neuro Endocrinol Lett 26(6):696-698
44. de Oliveira BF, Veloso CA, Nogueira-Machado JA, de Moraes EN, Santos RR, Cintra MT, Chaves MM (2012) Ascorbic acid, alpha-tocopherol, and beta-carotene reduce oxidative stress and proinflammatory cytokines in mononuclear cells of Alzheimer's disease patients. Nutr Neurosci. doi:10.1179/1476830512Y.0000000019
45. Rinaldi P, Polidori MC, Metastasio A et al (2003) Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging 24(7):915-919. doi:10.1016/S0197-4580(03)00031-9 (Pubitemid 36962976)
46. Arora A, Willhite CA, Liebler DC (2001) Interactions of beta-carotene and cigarette smoke in human bronchial epithelial cells. Carcinogenesis 22(8):1173-1178. doi:10.1093/carcin/22.8.1173 (Pubitemid 32737331)
47. Kontush A, Mann U, Arlt S, Ujeyl A, Lührs C, Müller-Thomsen T, Beisiegel U (2001) Influence of vitamin E and C supplementation on lipoprotein oxidation in patients with Alzheimer's disease. Free Radic Biol Med 31(3):345-354. doi:10.1016/S0891-5849(01)00595-0 (Pubitemid 32675340)
48. Giblin FJ (2000) Glutathione: a vital lens antioxidant. J Ocul Pharmacol Ther 16(2):121-135
49. Spiteller G (2001) Lipid peroxidation in aging and age-dependent diseases. Exp Gerontol 36(9):1425-1457. doi:10.1016/S0531-5565(01)00131-0
50. Praticò D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ (2002) Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol 59(6):972-976. doi:10.1001/archneur.59.6.972 (Pubitemid 34640757)
51. Montine KS, Quinn JF, Zhang J, Fessel JP, Roberts LJ, Morrow JD, Montin TJ (2004) Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids 128:117-124. doi:10.1016/j. chemphyslip.2003.10.010 (Pubitemid 38167381)
52. Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, Markesbery WR (2005) Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64(7):1152-1156. doi:10.1212/01.WNL. 0000156156.13641.BA
53. Markesbery WR, Lovell MA (2007) Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment. Arch Neurol 64(7):954-956. doi:10.1001/archneur. 64.7.954 (Pubitemid 47047994)
54. Rath M (2003) External and inherited cardiovascular risks: in: Rath M, 4th eds. Why animals don't get heart attacks, published by Dr. Rath Health Foundation
55. Husebye E, Engedal K (1992) The patterns of motility are maintained in the human small intestine throughout the process of aging. Scand J Gastroenterol 27(5):397-404. doi:10.3109/00365529209000095
56. Lloret A, Badía MC, Mora NJ, Pallardó FV, Alonso MD, Viña J (2009) Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. J Alzheimers Dis 17(1):143-149